drugset

drugset / Trial / NCT00865033

A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions

NCT00865033 ↗

Phase 1 Completed 32 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.

Timeline

Start: 2005-11
Primary completion: 2005-11
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	1000 mg	—

Indications